Octreotide: Effects in experimental severe acute pancreatitis. Analysis of survival, biochemical findings and histomorphometry

Revista Espanola de Enfermedades Digestivas

Volumn 89, Issue 2, 1997, Pages 109-115

  Sanchez Manuel J ^a   Landa Garcia J I ^a   Seco Gil, J L ^a   Velasco Oses, A ^a   Coma Del Corral, M J ^a   Vaquero Puerta, C ^a   Santamaria Garcia J L ^a  

^a NONE

Author keywords

acute experimental pancreatitis; octreotide

Indexed keywords

AMYLASE; LACTATE DEHYDROGENASE; OCTREOTIDE; TAUROCHOLIC ACID; TRIACYLGLYCEROL LIPASE; CHOLAGOGUE;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFICACY; ENZYME ACTIVITY; MALE; MORTALITY; NONHUMAN; PANCREATITIS; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; ACUTE DISEASE; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG SCREENING; METABOLISM; PATHOLOGY; WISTAR RAT;

ACUTE DISEASE; ANALYSIS OF VARIANCE; ANIMALS; CHOLAGOGUES AND CHOLERETICS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MALE; OCTREOTIDE; PANCREATITIS; RATS; RATS, WISTAR; TAUROCHOLIC ACID;

EID: 84920289646     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Domínguez-Muñoz JE, Carballo F, Garcia MJ, et al. Monitoring of serum proteinase-antiproteinase balance and systemic inflammatory response in prognostic evaluation of acute pancreatitis. Results of a prospective multicenter study. Dig Dis Sci. 1993;38:507-513.
2. Guilleret J, Guillemin G. Pancreatitis on the continent of Europe. In Surgical Diseases of the Pancreas. Lea & Febiger, Philadelphia 1987;pp 241-249.
3. Meshkinpour H, Molinari MD, Gardner L, et al. Cimetidine in the treatment of acute alcoholic pancreatitis. A randomized double blind trial study. Gastroenterology. 1979;77: 687-690.
4. Renner E, Savage WT, Pantoja JL, et al. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases. Dig Dis Sci. 1985;30:1004-1018.
5. Tykkä HT, Mahlberg KL, Pantzar PJ, et al. Phospholipase A2 inhibitors and their possible clinical use in the treatment of acute pancreatitis. Scand J Gastroenterology. 1980;15: 519.
6. Tykkä HT, Vaittinen EJ, Mahlberg KL, et al. A randomized double-blind study using CaNa2-EDTA, a phospholipase A2 inhibitor, in the management of human pancreatitis. Scand J Gastroenterol. 1985;20:5-12.
7. Camero JL, Mehigan D, Zuidema GD. Evaluation of atropine in acute pancreatitis. Surg Gynecol Obstet. 1979;148: 206-208.
8. Gogbill CL, Song KT. Acute pancreatitis. Arch Surg. 1970; 100:673-676.
9. Constantinescu C, Piu R, Straja D. 5-FU in the treatment of acute pancreatitis. Indications for and efficacy of its use. Rev Med Interna. 1989;41:443-448.
10. Johnson RM, Barone RW, Newson BL, et al. Treatment of experimental acute pancreatitis with 5-FU. Am J Surg. 1973;125:211-222.
11. Saario IA. 5-FU in the treatment of acute pancreatitis. Am J Surg. 1983;145:349-352.
12. Dürr HK, Maroske D, Zelder O, et al. Glucagon therapy of acute pancreatitis. Report of a double blind trial. Gut. 1978;19:175-179.
13. Enight MK, Condon JR, Smith R. Posible use of glucagon in the treatment of pancreatitis. Br Med J. 1971;2:440.
14. Jarete L, Lacy PE. Effect of glucagon on the acinar portion of the pancreas. Endocrinology. 1962;70:867.
15. MCR Working party. Death from acute pancreatitis. MCR multicentre trial of glucagon and aprotinine. Lancet. 1977; II:623-635.
16. Mercadier M, Chicot JP, Clot JP. Le glucagon dans le traitament des affections pancreatiques. Med Chir Dig. 1974;3:101.
17. Necheles J. Effects of glucagon on external secretion of the pancreas. Am J Physiol. 1957;191:395.
18. Salter JM, Davidson IWF, Best CH. The pathologic effects of large amounts of glucagon. Diabetes. 1957;6:248.
19. Sweeting JG. The effects of glucagon on bile and pancreatic juice. Gastroenterology. 1968;54:1276.
20. Annibale B, Ribaldi S, Anania MC, et al. Somatostatin infused during acute pancreatitis retains its biological activity. Pancreas. 1989;4:674-679.
21. Baxter JN, Jenkins SA, Day DW, et al. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg. 1985;72:382-385.
22. Lankisch PG, Koop H, Wincker K, et al. Somatostatin therapy of acute experimental pancreatitis. Cut. 1977;18: 713-716.
23. Mann NS, Manch MJ, Barnett R. Intraductal somatostatin protects against experimentally induced pancreatitis. Gastroenterology. 1980;78:777.
24. Rueda JC, Argüello JM, Ortega L, et al. Somatostatina en el tratamiento de la pancreatitis aguda establecida y severa en la rata. Rev Esp Enf Digest. 1991;80:183-188.
25. Sans-Segarra M, Osorio A, Ferrer E, et al. Efecto de la somatostatina en la pancreatitis aguda experimental. Cir Esp. 1990;43:524-527.
26. Schwedes U, Althoff PH, Klempa I, et al. Effect of somatostatin on bile induced haemorrhasic pancreatitis in the dog. Horm Metab Res. 1979;11:655-661.
27. Hollender LF. Traitment chirurgical de la pancreatite aigue. Schweiz Med Wochenschr. 1976;106:266-270.
28. Imrie CW, Benjamin IS, Ferguson JC, et al. A single-center, double blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978;65:337-341.
29. MCR. Multicenter trial. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut. 1980;21:334.
30. Trapnell JE, Talbot CH, Chir M. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974; 61:177-182.
31. Kontinen YP. Epsilon-aminocaproic acid in the treatment of acute pancreatitis. Scand J Gastroenterol. 1971;6:715-718.
32. Meinel J, Wolff E. Die Behandlung der akuten Pankreatitis mit dem antifibrinolytikum PAMBA. Dch Gesundheitsweesen. 1975;30:127-130.
33. Naeije R, Salingret E, Clumeck N, et al. Is nasogastric suction necessary in acute pancreatitis? Br Med J. 1978;2: 659.
34. Navarro S, Ros E, Aused R, et al. Comparison of fasting, nasogastric suction and cimetidine in the treatment of acute pancreatitis. Digestion. 1984;30:224-230.
35. Dobosz M, Sledzinski Z, Basinski A. Effect on hemodynamics of therapeutic infusion of Gabexate mesilate (FOY) in experimental acute pancreatitis. Res Exp Med Berl. 1989;189:77-84.
36. Niederau C, Crass RA, Silver G, et al. Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage and a potent protease inhibitor. Gastroenterology. 1988;95:1648-1657.
37. Wismer JR, Ozana S, Renner JG. The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat. Int J Pancreatol 1989;4:383-390.
38. Steer ML. How and where does acute pancreatitis begin? Arch Surg. 1992;127:1350-1353.
39. Ais G. Influencia de la somatostatina sobre las alteraciones hemodinámicas inducidas por la pancreatitis aguda experimental. XVIII Cong. Nac. Cir. (comunic.). Madrid, 1990.
40. Landa JI, Arias J, Gómez M. Efectos de la somatostatina sobre la supervivencia y niveles de PGE-2 en un modelo de pancreatitis necrohemorrágica en el perro. Gastroenterol Hepatol. 1991;14:481-487.
41. Jost J. Der Einfluss von Somatostatin auf die akute Pankreatitis. Chir Praxis. 1985;35:633-640.
42. McKay CJ, Imrie CW, Baxter JN. Somatostatin and somatostatin analogues -are they indicated in the management of acute pancreatitis? Gut. 1993;34:1622-1626.
43. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-1140.
44. Astorga R. Análogo de la somatostatina: perspectivas actuales y futuras. Med Clin (Barc). 1989;93:508-515.
45. Binmoeller KF, Dumas R, Harris AG, et al. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci. 1992;37:773-777.
46. Comi RJ, Maton PN, Go VLW (NIH Conference). Somatostatin and Somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110:35-50.
47. Díez JJ, Salvador J, Gómez-Pan A. Aplicaciones actuales y nuevas perspectivas terapéuticas de los análogos de la somatostatina. Endocrinología. 1992;39:456-467.
48. Grosman I, Simon D. Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide. Am J Gastroenterol. 1990;85:1061-1072.
49. Harris AG. Future medical prospects for Sandostatin. Metabolism. 1990;9:180-185.
50. Hopman WPM, van Liessum PA, Pieters GFFM, et al. Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201-995). Digestion. 1990;45(supl 1):72-76.
51. Hurst RD, Modlin IM. The therapeutic role of octreotide in the manasement of surgical disorders. Am J Surg. 1991; 162:499-507.
52. Mozell EJ, Woltering EA, O'Dorisio TM. Non-endocrine applications of somatostatin and octreotide acetate: facts and nights of fancy. Dis Mon. 1991;37:754-759.
53. O'Donnell LJD, Farthing MJG. Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases. Gut. 1989;30:1165-1172.
54. Stolk MFJ, van Erpecum KJ, Koppeschaar HPF, et al. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly. Gut. 1993;34:808-813.
55. Williams G, Anderson JV, Williams SJ, et al. Clinical evaluation of SMS 201-995. Acta Endocrinol. 1987;suppl 286:26-36.
56. Williams ST, Woltering EA, O'Dorisio ThM, et al. Effect of octreotide acetate on pancreatic exocrine function. Am J Surg. 1989;157:459-462.
57. Faber SM, Romeu J, Mendelsohn RA, et al. Inhibition of pancreatic reactions using sandostatin (SMS 201-995) as a prophylactic agent in patients undergoing endoscopic retrograde cholangiopancreatography/endoscopic sphincterotomy. Gastroenterology. 1990;98 (supl):p.A216.
58. Tulassay Z, Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc. 1991;37:48-50.
59. Büchler M, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg. 1992;163:125-131.
60. Gullo L, Barbara L. Treatment of pancreatic pseudocysts with octreotide. Lancet. 1991;338:540-541.
61. Ahren B, Tranberg GK, Bengmark S. Treatment of pancreatic fistula with the somatostin analogue SMS 201-995. Br J Surg. 1988;75:718.
62. Cooper MM, Wright FH, Smith JL, et al. Successful treatment of a high-output fistula with a somatostatin analogue following pancreas transplantation. Transplantation Proceedings. 1989;21:3738-3741.
63. Faroux R, Bretagne JF, Le Jean-Colin I, et al. Traitement d'une fistule pancréatique externe par la somatostatine retard. Presse Méd. 1987;16:1379.
64. Kwan D, Aufses Jr AH. Short-term administration of SMS 201-995 in the management of an external pancreatic fistula. Am J Gastroenterol. 1989;84:326-328.
65. Prinz RA, Pickleman J, Hoffman JP. Treatment of pancreatic cutaneous fistulas with a somatostatin analog. Am J Surg. 1988;155:36-42.
66. Landa JI, Ortega L, Llanos K, et al. Somatostatina y octreotida: diferentes efectos sobre un modelo de pancreatitis necrohemorraeica experimental. Cir Esp. 1993;53:243-247.
67. Editorial. Llegó la hora del octreótide. Lancet. 1990;336: 909-911 (edicion española).
68. Köhler E, Beglinger Ch, Dettwiler S, et al. Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas. 1986;1:154-159.
69. Pless J, Bauer W, Briner U, et al. Chemistry and pharmacology of SMS 201-995, a long acting octapeptide analogue of somatostatin. Scand J Gastroenterol. 1986;21: (suppl 119):54-64.
70. del Pozo E, Neufeld M, Schlüter K, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol (Kbh) 1986;111:433-439.
71. Rueda JC, Ortega L, Argüello JM, et al. Acute experimental pancreatitis in rat induced by sodium taurocholic acid: objective quantification of pancreatic necrosis. Virchows Archiv A Pathol Anat. 1992;420:117-120.
72. Rueda JC, Ortega L, Argüello JM, et al. Pancreatitis aguda experimental en la rata. Cuantificación de la necrosis pancreática tras la inyección retrógrada ductal de taurocolato sódico. Rev Esp Enf Digest. 1991;80:178-182.
73. Augelli NV, Hussain SM, McKain MM, et al. Effect of SMS 201-995 (a long-acting somatostatin analog) on bile-induced acute hemorrhagic pancreatitis in the dog. Am Surg. 1989;55:389-391.
74. Davliakos GP, Petraiuolo WJ, Sell HWJr, et al. Treatment of experimentally induced pancreatitis in ex vivo perfused canine pancreas with the somatostatin analogue octreotide. Curr Surg. 1990;47:343-345.
75. Murayama KM, Drew JB, Joehl RJ. Does somatostatin analogue prevent experimental acute pancreatitis? Arch Surg. 1990;12:1570-1572.
76. Beechey-Newman N, Lee W, Wilkinson M, et al. Treatment wit hig dose octreotide improve the clinical course of acute pancreatitis. Gut. 1991;32:p.A558.
77. Ratía T, Arribas I, Iritia M, et al. Acción del octreotido en pancreatitis aguda. Experiencia en rata inducida por inyección ductal. Rev Esp Enf Digest. 1990;77(supl I):59.
78. Landa JI, Llanos K, Grau M, et al. Somatostatina (SRIF) y Octreotide (SMS 201-995): diferentes efectos sobre un modelo de pancreatitis necrohemorragica experimental. Rev Esp Enf Digest. 1992;82:282-283.
79. Gudgeon AM, Healt DI, Hurley P, et al. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet. 1990;1:4-8.
80. Landa JI, Arias J, Gomez M, et al. Péptidos de activación del tripsinógeno y necrosis pancreática. Cir Esp. 1992;51: 32-34.
81. van Ooijen B, Tinga CJ, Kort WJ, et al. Effects of long-acting somatostatin analog (SMS 201-995) on eicosanoid synthesis and survival in rats with acute necrotizing pancreatitis. Dig Dis Sci. 1992;37:1434-1440.